Abstract Number: 1713 • ACR Convergence 2021
Risk of Serious Infections in Offspring Exposed in Utero to Ustekinumab or Vedolizumab
Background/Purpose: Ustekinumab, an IL-12/23 inhibitor, is indicated in adult patients with inflammatory bowel disease (IBD), psoriasis (PsO), and psoriatic arthritis (PsA) and vedolizumab, an α4β7…Abstract Number: 0489 • ACR Convergence 2020
Prevalence, Incidence, and Cause-Specific Mortality of Rheumatoid Arthritis-Associated Interstitial Lung Disease Among Older Patients with Rheumatoid Arthritis: A Nationwide Cohort Study
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is one of the most serious extra-articular RA manifestations and is more common in older patients. Registry-based RA-ILD…Abstract Number: 1022 • ACR Convergence 2020
Declining In-hospital Mortality Gap in Lupus Compared to Non-lupus Hospitalizations: A National Study
Background/Purpose: Lupus is a serious, multi-system autoimmune disease that affects young people. Mortality is increased by over 2-3 fold compared to the general population. Time-trends…Abstract Number: 0541 • ACR Convergence 2020
Suboptimal Vaccination Coverage with Influenza, Pneumococcal and Herpes Zoster Vaccines Among Adult Patients with Autoimmune Inflammatory Rheumatic Diseases in a Nationwide Health Care Plan
Background/Purpose: Autoimmune inflammatory rheumatic diseases (AIIRD) increase the susceptibility to infections. Immunisation against vaccine-preventable diseases is recommended for patients with AIIRD by most international medical…Abstract Number: 1026 • ACR Convergence 2020
The Incidence, Mortality, and Economic Burden of Potentially Preventable Infections in Systemic Lupus Erythematosus Patients
Background/Purpose: Streptococcus pneumoniae, Herpes zoster, and influenza infections are common and potentially preventable causes of morbidity and mortality. Vaccinations have been shown to reduce infection…Abstract Number: 0556 • ACR Convergence 2020
Recent Use, Missed Doses and Discontinuation of Infliximab in New-users: Comparisons of Biosimilar and Originator Exposures
Background/Purpose: Biosimilar infliximab offers a potentially lower‐cost treatment option compared to its bio‐originator. However, uptake of biosimilars in general in North America has been slow.…Abstract Number: 1028 • ACR Convergence 2020
Probabilistic Linkage of a Cohort of Individuals with Symptoms Suggestive of Early Spondyloarthritis and the French National Healthcare Database
Background/Purpose: DESIR is the French cohort of patients with symptoms suggestive of early axial Spondyloarthritis (axSpA). Our objective was to enrich this cohort with claims…Abstract Number: 0566 • ACR Convergence 2020
Healthcare Utilization and Costs Prior to Diagnosis of ANCA Vasculitis in Medicare Beneficiaries
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA) vasculitis (AV) is a complex group of autoimmune disorders affecting blood vessels in multiple organ systems. Delays in diagnosis are…Abstract Number: 1031 • ACR Convergence 2020
Real World Treatment Patterns Among Patients with Psoriatic Arthritis Treated with Ixekizumab
Background/Purpose: Psoriatic arthritis (PsA) is a systemic condition estimated to affect 0.05%-0.25% of the United States (US)1 population. With approval of ixekizumab (a selectively binding…Abstract Number: 0580 • ACR Convergence 2020
Risk of Severe Acute Localized Reactions for Different Intra-Articular Hyaluronic Acid Knee Injections in a Real World Setting
Background/Purpose: Case reports of severe acute localized reactions (SALR) following intra-articular (IA) hyaluronic acid (HA) injections for knee osteoarthritis (OA) have been described. These have…Abstract Number: 1281 • ACR Convergence 2020
Opioid-Related Encounters as a Predictor of 30-Day Readmissions in Lupus
Background/Purpose: One in four Medicare hospitalizations with systemic lupus erythematosus (SLE) results in readmission within 30 days, with “injuries and poisonings” as the second most…Abstract Number: 0678 • ACR Convergence 2020
Patient Characteristics and Patterns of Urate-lowering Treatments in Older Patients with Incident Gout
Background/Purpose: Gout is a common inflammatory arthritis caused by monosodium urate crystal deposition in the joints. Despite this well-understood pathophysiologic mechanism of disease and ACR and EULAR…Abstract Number: 1423 • ACR Convergence 2020
Declining In-Hospital Mortality in Vasculitis: A 17-year U.S. National Study
Background/Purpose: To our knowledge, only a few population-based studies for vasculitis mortality exist; and most are limited to vasculitis sub-types. Therefore, our study objective was…Abstract Number: 0689 • ACR Convergence 2020
The Changing Epidemiology of Inpatient Gout and Associated Mortality: A 17-year National Study
Background/Purpose: Knowledge gaps exist regarding time-trends for the main causes (Cardiac/renal disease vs. infections) hospitalizations in gout. Therefore, we examined whether specific causes (cardiovascular, renal,…Abstract Number: 1475 • ACR Convergence 2020
Predictors of Thirty-Day Hospital Readmissions in Systemic Lupus Erythematosus in the US: A Nationwide Study
Background/Purpose: For individuals with systemic lupus erythematosus (SLE), hospital readmission rate is associated with quality of care and prognosis. Our objective was to evaluate independent…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- Next Page »